SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
| REVA Medical, Inc. | ||
| (Name of Issuer) | ||
| Common Stock, par value $0.0001 per share | ||
| (Title of Class of Securities) | ||
| 76133E 109 | ||
| (CUSIP Number) | ||
| December 31, 2016 | ||
| (Date of Event Which Requires Filing of this Statement) | ||
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
CUSIP No. 76133E 109 | ||
| 1 | NAMES OF REPORTING PERSONS | ||
| Medtronic plc | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)* | ||
(a) ¨ | |||
(b) ¨ | |||
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||
| Ireland | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER | |
| 1,732,260 (1) | |||
| 6 | SHARED VOTING POWER | ||
| 0 | |||
| 7 | SOLE DISPOSITIVE POWER | ||
| 1,732,260 (1) | |||
| 8 | SHARED DISPOSITIVE POWER | ||
| 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICALLY OWNED BY EACH REPORTING PERSON | ||
| 1,732,260 (1) | |||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||
| 4.1% (2) | |||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | ||
| OO | |||
| (1) | Ownership consists of 13,526,095 CHESS Depositary Interests (“CDIs”) and 379,651 shares of common stock. Each CDI represents one-tenth of a share of common stock. |
| (2) | The percentage is based upon 42,742,819 shares of common stock outstanding as of November 1, 2016, as disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 as filed with the Securities and Exchange Commission on November 9, 2016. |
SCHEDULE 13G
CUSIP No. 76133E 109 | ||
| 1 | NAMES OF REPORTING PERSONS | ||
| Medtronic, Inc. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)* | ||
(a) ¨ | |||
(b) ¨ | |||
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||
| MN | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER | |
| 1,732,260 (1) | |||
| 6 | SHARED VOTING POWER | ||
| 0 | |||
| 7 | SOLE DISPOSITIVE POWER | ||
| 1,732,260 (1) | |||
| 8 | SHARED DISPOSITIVE POWER | ||
| 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICALLY OWNED BY EACH REPORTING PERSON | ||
| 1,732,260 (1) | |||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||
| 4.1% (2) | |||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) | ||
| CO | |||
| (1) | Ownership consists of 13,526,095 CHESS Depositary Interests (“CDIs”) and 379,651 shares of common stock. Each CDI represents one-tenth of a share of common stock. |
| (2) | The percentage is based upon 42,742,819 shares of common stock outstanding as of November 1, 2016, as disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 as filed with the Securities and Exchange Commission on November 9, 2016. |
Explanatory Note
This Amendment No. 3 to the Schedule 13G filed by Medtronic, Inc. on March 22, 2012, as amended on February 14, 2013 and February 16, 2016, regarding its ownership of securities of REVA Medical, Inc. is being filed to reflect that, as of December 31, 2016, Medtronic, Inc. and Medtronic plc have ceased to be the beneficial owner of more than five percent of the outstanding common stock of REVA Medical, Inc.
Item 1(a) Name of Issuer:
REVA Medical, Inc.
Item 1(b) Address of Issuer’s Principal Executive Offices:
5751 Copley Drive
San Diego, CA 92111
Item 2(a) Name of Person Filing:
Medtronic plc
Medtronic, Inc.
Item 2(b) Address of Principal Business Office or, if None, Residence:
Medtronic plc: 20 Lower Hatch Street, Dublin 2, Ireland
Medtronic, Inc.: 710 Medtronic Parkway, Minneapolis, MN 55432
Item 2(c) Citizenship:
Medtronic plc: Ireland
Medtronic, Inc.: MN
Item 2(d) Title of Class of Securities:
Common Stock
Item 2(e) CUSIP Number:
76133E 109
| Item 3 | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) | Broker or dealer registered under Section 15 of the Act. |
| (b) | Bank as defined in Section 3(a)(6) of the Act. |
| (c) | Insurance company as defined in Section 3(a)(19) of the Act. |
| (d) | Investment company registered under Section 8 of the Investment |
Company Act of 1940.
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E). |
| (f) | An employee benefit plan or endowment fund in accordance with |
§ 240.13d-1(b)(1)(ii)(F).
| (g) | A parent holding company or control person in accordance with |
§ 240.13d-1(b)(1)(ii)(G).
| (h) | A savings association as defined in Section 3(b) of the Federal |
Deposit Insurance Act.
| (i) | A church plan that is excluded from the definition of an investment |
company under Section 3(c)(14) of the Investment Company Act.
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
(k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
Item 4 Ownership.
See Cover Pages, Items 5 through 11.
Item 5 Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .
Item 6 Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7 Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8 Identification and Classification of Members of the Group.
Not applicable.
Item 9 Notice of Dissolution of Group.
Not applicable.
Item 10 Certifications.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
| Exhibits | Joint Filing Agreement, dated February 16, 2016, between Medtronic plc and Medtronic, Inc., incorporated by reference to Exhibit to Amendment No. 2 to Schedule 13G filed by Medtronic plc and Medtronic, Inc. on February 16, 2016. |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2017 Medtronic plc
/s/ Karen Parkhill
Name: Karen Parkhill
Title: Executive Vice President and Chief Financial Officer
Dated: February 13, 2017 Medtronic, Inc.
/s/ Karen Parkhill
Name: Karen Parkhill
Title: Executive Vice President and Chief Financial Officer